Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Market Covaris' DNA Shearing Tech for Use with SureSelect

Premium

Agilent Technologies and Covaris said this week that they have signed a co-marketing agreement.

Under the agreement, Agilent will market Covaris' S2 DNA shearing system for use with its SureSelect Target Enrichment System, a solution-based DNA selection method for high-throughput sequencing.

Covaris has also developed a SureSelect accessory kit to help Agilent customers integrate its shearing method, which is based on the company's adaptive focused acoustic technology, into their workflows.

Agilent said it will continue to work with Covaris to develop new SureSelect protocols and products.

"So far, SureSelect customers have found our protocols to be very easy to follow and extremely robust, so I believe we've made a good choice to recommend the use of the Covaris S2," said Fred Ernani, Agilent's senior product manager for emerging genomic applications, in a statement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.